SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and adv...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2023-09, Vol.25 (9), p.2707-2717
Main Authors: Serrano, César, Álvarez, Rosa, Carrasco, Juan Antonio, Marquina, Gloria, Martínez-García, Jerónimo, Martínez-Marín, Virginia, Sala, María Ángeles, Sebio, Ana, Sevilla, Isabel, Martín-Broto, Javier
Format: Article
Language:English
Subjects:
Clinical Guides in Oncology
Medicine
Medicine & Public Health
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.
ISSN:1699-3055
1699-048X
1699-3055
DOI:10.1007/s12094-023-03177-7